Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

Vedolizumab Treatment in Extra-Intestinal Manifestations in Inflammatory Bowel Disease: A Systematic Review.

Chateau T, Bonovas S, Le Berre C, Mathieu N, Danese S, Peyrin-Biroulet L.

J Crohns Colitis. 2019 May 10. pii: jjz095. doi: 10.1093/ecco-jcc/jjz095. [Epub ahead of print]

PMID:
31076751
2.

Systematic Review of Tumor Necrosis Factor Antagonists in Extraintestinal Manifestations in Inflammatory Bowel Disease.

Peyrin-Biroulet L, Van Assche G, Gómez-Ulloa D, García-Álvarez L, Lara N, Black CM, Kachroo S.

Clin Gastroenterol Hepatol. 2017 Jan;15(1):25-36.e27. doi: 10.1016/j.cgh.2016.06.025. Epub 2016 Jul 5. Review.

PMID:
27392760
3.

Impact of vedolizumab therapy on extra-intestinal manifestations in patients with inflammatory bowel disease: a multicentre cohort study nested in the OBSERV-IBD cohort.

Tadbiri S, Peyrin-Biroulet L, Serrero M, Filippi J, Pariente B, Roblin X, Buisson A, Stefanescu C, Trang-Poisson C, Altwegg R, Marteau P, Vaysse T, Bourrier A, Nancey S, Laharie D, Allez M, Savoye G, Gilletta C, Gagniere C, Vuitton L, Viennot S, Aubourg A, Pelletier AL, Bouguen G, Abitbol V, Fumery M, Claudepierre P, Bouhnik Y, Amiot A; GETAID OBSERV-IBD study group.

Aliment Pharmacol Ther. 2018 Feb;47(4):485-493. doi: 10.1111/apt.14419. Epub 2017 Dec 18.

PMID:
29250803
4.

Effects of Vedolizumab Therapy on Extraintestinal Manifestations in Inflammatory Bowel Disease.

Fleisher M, Marsal J, Lee SD, Frado LE, Parian A, Korelitz BI, Feagan BG.

Dig Dis Sci. 2018 Apr;63(4):825-833. doi: 10.1007/s10620-018-4971-1. Epub 2018 Feb 26. Review.

5.

Extraintestinal Manifestations in Vedolizumab and Anti-TNF-Treated Patients With Inflammatory Bowel Disease.

Dubinsky MC, Cross RK, Sandborn WJ, Long M, Song X, Shi N, Ding Y, Eichner S, Pappalardo B, Ganguli A, Wang A.

Inflamm Bowel Dis. 2018 Apr 13. doi: 10.1093/ibd/izy065. [Epub ahead of print]

PMID:
29668916
6.

Extraintestinal manifestations of inflammatory bowel disease and the influence of smoking.

Roberts H, Rai SN, Pan J, Rao JM, Keskey RC, Kanaan Z, Short EP, Mottern E, Galandiuk S.

Digestion. 2014;90(2):122-9. doi: 10.1159/000363228. Epub 2014 Oct 1.

PMID:
25277851
7.

Efficacy of infliximab for extraintestinal manifestations of inflammatory bowel disease.

Siemanowski B, Regueiro M.

Curr Treat Options Gastroenterol. 2007 Jun;10(3):178-84.

PMID:
17547856
8.

Effects of Vedolizumab in Patients with Primary Sclerosing Cholangitis and Inflammatory Bowel Diseases.

Lynch KD, Chapman RW, Keshav S, Montano-Loza AJ, Mason AL, Kremer AE, Vetter M, de Krijger M, Ponsioen CY, Trivedi P, Hirschfield G, Schramm C, Liu CH, Bowlus CL, Estes DJ, Pratt D, Hedin C, Bergquist A, de Vries AC, Janneke van der Woude C, Yu L, Assis DN, Boyer J, Ytting H, Hallibasic E, Trauner M, Marschall HU, Daretti LM, Marzioni M, Yimam KK, Perin N, Floreani A, Beretta-Piccoli BT, Rogers JK; International Primary Sclerosing Cholangitis Study Group (IPSCSG), Levy C.

Clin Gastroenterol Hepatol. 2019 May 14. pii: S1542-3565(19)30523-3. doi: 10.1016/j.cgh.2019.05.013. [Epub ahead of print]

PMID:
31100458
9.
10.

Diagnosis and therapeutic management of extra-intestinal manifestations of inflammatory bowel disease.

Trikudanathan G, Venkatesh PG, Navaneethan U.

Drugs. 2012 Dec 24;72(18):2333-49. doi: 10.2165/11638120-000000000-00000. Review.

PMID:
23181971
11.

Vedolizumab therapy is ineffective for primary sclerosing cholangitis in patients with inflammatory bowel disease: A GETAID multicentre cohort study.

Caron B, Peyrin-Biroulet L, Pariente B, Bouhnik Y, Seksik P, Bouguen G, Caillo L, Laharie D, Carbonnel F, Altwegg R, Reenaers C, Serrero M, Trang-Poisson C, Nancey S, Filippi J, Abitbol V, Savoye G, Vuitton L, Viennot S, Fumery M, Reymond M, Bronowicki JP, Reimund JM, Amiot A; GETAID.

J Crohns Colitis. 2019 May 6. pii: jjz088. doi: 10.1093/ecco-jcc/jjz088. [Epub ahead of print]

PMID:
31056693
12.

Skin Manifestations of Inflammatory Bowel Disease.

Greuter T, Navarini A, Vavricka SR.

Clin Rev Allergy Immunol. 2017 Dec;53(3):413-427. doi: 10.1007/s12016-017-8617-4. Review.

PMID:
28643285
13.

Vedolizumab in patients with concurrent primary sclerosing cholangitis and inflammatory bowel disease does not improve liver biochemistry but is safe and effective for the bowel disease.

Christensen B, Micic D, Gibson PR, Yarur A, Bellaguarda E, Corsello P, Gaetano JN, Kinnucan J, Rao VL, Reddy S, Singh S, Pekow J, Rubin DT.

Aliment Pharmacol Ther. 2018 Mar;47(6):753-762. doi: 10.1111/apt.14525. Epub 2018 Jan 29.

14.

Biologic therapy in the management of extraintestinal manifestations of inflammatory bowel disease.

Barrie A, Regueiro M.

Inflamm Bowel Dis. 2007 Nov;13(11):1424-9. Review.

PMID:
17567879
15.

Chronological Order of Appearance of Extraintestinal Manifestations Relative to the Time of IBD Diagnosis in the Swiss Inflammatory Bowel Disease Cohort.

Vavricka SR, Rogler G, Gantenbein C, Spoerri M, Prinz Vavricka M, Navarini AA, French LE, Safroneeva E, Fournier N, Straumann A, Froehlich F, Fried M, Michetti P, Seibold F, Lakatos PL, Peyrin-Biroulet L, Schoepfer AM.

Inflamm Bowel Dis. 2015 Aug;21(8):1794-800. doi: 10.1097/MIB.0000000000000429.

16.

An induction or flare of arthritis and/or sacroiliitis by vedolizumab in inflammatory bowel disease: a case series.

Varkas G, Thevissen K, De Brabanter G, Van Praet L, Czul-Gurdian F, Cypers H, De Kock J, Carron P, De Vos M, Hindryckx P, Arts J, Vanneuville I, Schoenaers P, Claerhout B, Abreu M, Van den Bosch F, Elewaut D.

Ann Rheum Dis. 2017 May;76(5):878-881. doi: 10.1136/annrheumdis-2016-210233. Epub 2016 Nov 29.

PMID:
27899374
17.

Systematic Review and Meta-Analysis: Preoperative Vedolizumab Treatment and Postoperative Complications in Patients with Inflammatory Bowel Disease.

Law CCY, Narula A, Lightner AL, McKenna NP, Colombel JF, Narula N.

J Crohns Colitis. 2018 Apr 27;12(5):538-545. doi: 10.1093/ecco-jcc/jjy022. Review.

PMID:
29718245
18.

Tolerability of selective cyclooxygenase 2 inhibitors used for the treatment of rheumatological manifestations of inflammatory bowel disease.

Miao XP, Li JS, Ouyang Q, Hu RW, Zhang Y, Li HY.

Cochrane Database Syst Rev. 2014 Oct 23;(10):CD007744. doi: 10.1002/14651858.CD007744.pub2. Review.

PMID:
25340915
19.

Ocular Manifestations in Inflammatory Bowel Disease Are Associated with Other Extra-intestinal Manifestations, Gender, and Genes Implicated in Other Immune-related Traits.

Taleban S, Li D, Targan SR, Ippoliti A, Brant SR, Cho JH, Duerr RH, Rioux JD, Silverberg MS, Vasiliauskas EA, Rotter JI, Haritunians T, Shih DQ, Dubinsky M, Melmed GY, McGovern DP.

J Crohns Colitis. 2016 Jan;10(1):43-9. doi: 10.1093/ecco-jcc/jjv178. Epub 2015 Oct 8.

20.

Association of Vedolizumab Level, Anti-Drug Antibodies, and α4β7 Occupancy With Response in Patients With Inflammatory Bowel Diseases.

Ungar B, Kopylov U, Yavzori M, Fudim E, Picard O, Lahat A, Coscas D, Waterman M, Haj-Natour O, Orbach-Zingboim N, Mao R, Chen M, Chowers Y, Eliakim R, Ben-Horin S.

Clin Gastroenterol Hepatol. 2018 May;16(5):697-705.e7. doi: 10.1016/j.cgh.2017.11.050. Epub 2017 Dec 7.

PMID:
29223444

Supplemental Content

Support Center